Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

gallium Ga 68 dotatate 690Y-octreotide, DOTA-Tyr(3)- 3Magnetic Resonance Spectroscopy 23-Iodobenzylguanidine 2lutetium Lu 177 dotatate 1lanreotide 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Single Photon Emission Computed Tomography Computed Tomography 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Metformin 1Iodine-123 1Ga(III)-DOTATOC 168Ga-pentixafor 168Ga-FAPI 164Cu-SARTATE 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neuroendocrine Tumors × 64Cu-SARTATE × Clear all
NCT04440956 2020-06-22

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Clarity Pharmaceuticals Ltd

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡